Molecular Imaging and Biology · Nov 16, 2026

FDG PET Biodistribution Patterns of Patients on GLP-1 Therapies

By DeGeorge C, Simon B, DeSai C

Purpose The use of glucagon-like peptide-1 (GLP-1) therapies continues to increase, but there is limited literature on their effect on fluorodeoxyglucose (FDG) biodistribution and minimal society guidelines. This study presents observations on a cohort of findings associated with GLP-1 use among patients undergoing oncologic FDG PET/CT, with attention to factors that may complicate image interpretation. Materials and Methods This retrospective observational study included 116 adult patients from a single academic center who reported use of a GLP-1. Medical information and demographic information were compiled, and images were analyzed for abnormal biodistribution. Statistical analysis was performed to determine association between these factors and atypical uptake. Results This study found areas of altered FDG biodistribution in 75.9% (88/116) of patients with uptake noted in the esophagus, small intestines, large intestines, and muscles. Muscle uptake was seen in 21.6% of patients including one patient whose scan was considered nondiagnostic. There was no significant association between muscle uptake and age, sex, BMI, time since last GLP-1 dose, NPO time, blood glucose level, individual GLP-1 medications, insulin usage, metformin usage, other antidiabetic drug usage, systemic steroid usage, or GI symptoms. However, there was a significant association with gastric solid contents (p value 0.01). Conclusions This observational study found that patients using GLP-1 therapies exhibit multiple areas of altered biodistribution. Notably, increased muscle uptake had a statistically significant association with concomitant gastric solid contents. There was no association with fasting time (which ranged from 6 to 24 h in our sample). As patients were often on other medications, including other medications for diabetes, uptake may be related to a combination of factors. Further studies are needed to delve into the causes of altered biodistribution on FDG PET/CT performed on patients taking GLP-1s, with close attention to patients with muscle uptake, to inform future guidelines on image interpretation and patient preparation.

doi.org/10.1007/s11307-026-02146-0Open accessInterventions

AgingResearch.News